<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03554291</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00005002</org_study_id>
    <secondary_id>1R61HL142539-01</secondary_id>
    <nct_id>NCT03554291</nct_id>
  </id_info>
  <brief_title>Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension</brief_title>
  <acronym>REHAB-PH</acronym>
  <official_title>Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, single-center, randomized placebo controlled trial of famotidine (an H2&#xD;
      receptor antagonist) in adults with pulmonary arterial hypertension. The study will evaluate&#xD;
      the safety and clinical efficacy of a 24-week course of famotidine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary arterial hypertension (PAH) is one of many conditions that put stress and strain on&#xD;
      the right side of the heart. This stress and strain can cause right heart failure. Although&#xD;
      there are medications to treat PAH, there are currently no medications that act directly on&#xD;
      the heart to improve right heart function. This is different than left heart failure where&#xD;
      one of the cornerstones of treatment is medication targeted at the heart to improve left&#xD;
      heart function.&#xD;
&#xD;
      Famotidine is a well-tolerated, over-the-counter, and inexpensive medication. Preliminary&#xD;
      results suggest that famotidine may help the right heart to adapt and strengthen when&#xD;
      stressed instead of fail; however, these results are suggestive and not definitive. A&#xD;
      randomized controlled trial is required to evaluate the possibility that famotidine can&#xD;
      impact right heart function.&#xD;
&#xD;
      Participants in the study will take famotidine or placebo for 24 weeks. They will have three&#xD;
      study visits at 0, 12, and 24 weeks. These visits will add 20-30 minutes to the standard&#xD;
      clinic visits at those time points and there will be an echocardiogram at weeks 0 and 24.&#xD;
      There will also be one phone visit at 4 weeks to check-in. Some participants may elect to&#xD;
      participate in exercise testing and/or right heart catheterization at weeks 0 and 24;&#xD;
      however, this is not required to participate in the trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Six-minute walk distance</measure>
    <time_frame>0 to 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>nt-pro-BNP</measure>
    <time_frame>0 to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) functional class</measure>
    <time_frame>0 to 24 weeks</time_frame>
    <description>NYHA functional class will be determined by a 10 question decision aid.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life (emPHasis-10 questionnaire)</measure>
    <time_frame>0 to 24 weeks</time_frame>
    <description>To determine whether famotidine improves health related quality of life as estimated by the emPHasis-10 score. Each item on the emPHasis-10 questionnaire is scored on a semantic differential six-point scale (0-5), with contrasting adjectives at each end. EmPHasis-10 scores range from 0 to 50 with higher scores indicating worse quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of escalation for PAH focused care (increased diuretics, escalating doses of pulmonary vasodilators, and/or adding additional pulmonary vasodilators)</measure>
    <time_frame>0 to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right ventricular function by echocardiogram</measure>
    <time_frame>0 to 24 weeks</time_frame>
    <description>TAPSE</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <condition>Right Heart Failure</condition>
  <arm_group>
    <arm_group_label>Famotidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20mg of oral famotidine (pill) daily&#xD;
Other names: Pepcid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily oral placebo (pill)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famotidine 20 MG</intervention_name>
    <description>Famotidine 20 mg capsule taken daily for 24 weeks.</description>
    <arm_group_label>Famotidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule taken daily for 24 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, age 18 to 80&#xD;
&#xD;
          -  WHO Group 1 Pulmonary Arterial Hypertension&#xD;
&#xD;
          -  NYHA Functional Class II, III, or IV at screening&#xD;
&#xD;
          -  Stable dose of pulmonary vasodilators for 30 days prior to randomization&#xD;
&#xD;
          -  Right heart catheterization within five years demonstrating a mean pulmonary arterial&#xD;
             pressure of ≥ 25 mmHg, occlusion pressure of ≤ 15 mmHg, and pulmonary vascular&#xD;
             resistance of ≥ 3 wood units&#xD;
&#xD;
          -  Participants with a right heart catheterization within five years demonstrating a mean&#xD;
             pulmonary arterial pressure of ≥ 25 mmHg and occlusion pressure of 15 - 20 mmHg will&#xD;
             be considered for inclusion if the pulmonary vascular resistance ≥ 9 wood units and&#xD;
             they are being treated with pulmonary arterial hypertension specific therapy&#xD;
&#xD;
          -  Able to walk with/without a walking aid for a distance of at least 50 meters&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Non-group 1 pulmonary hypertension or veno-occlusive disease&#xD;
&#xD;
          -  History of interstitial lung disease, unless subject has collagen vascular disease and&#xD;
             has pulmonary function testing conducted within 12 months demonstrating a total lung&#xD;
             capacity of ≥ 60 %&#xD;
&#xD;
          -  Has received or will receive an investigational drug, device, or study within 30 days&#xD;
             or during the course of study&#xD;
&#xD;
          -  Left sided myocardial disease as evidenced by left ventricular ejection fraction &lt; 40%&#xD;
&#xD;
          -  Any other clinically significant illness or abnormal laboratory values (measured&#xD;
             during the Screening period) that, in the opinion of the Investigator, might put the&#xD;
             subject at risk of harm during the study or might adversely affect the interpretation&#xD;
             of the study data&#xD;
&#xD;
          -  Anticipated survival less than 1 year due to concomitant disease&#xD;
&#xD;
          -  Regularly taking an H2 receptor antagonist within 30 days of enrollment&#xD;
&#xD;
          -  Creatinine clearance &lt; 30 mL/min&#xD;
&#xD;
          -  History of bariatric surgery&#xD;
&#xD;
          -  Current treatment for HIV&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter J Leary, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurie Hogl</last_name>
    <phone>206-543-8334</phone>
    <email>lalnaser@uw.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Hogl</last_name>
      <phone>206-543-8334</phone>
      <email>lalnaser@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Peter J Leary, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David D Ralph, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sam G Rayner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Leary PJ, Barr RG, Bluemke DA, Bristow MR, Kronmal RA, Lima JA, Ralph DD, Ventetuolo CE, Kawut SM. H2 receptor antagonists and right ventricular morphology: the MESA right ventricle study. Ann Am Thorac Soc. 2014 Nov;11(9):1379-86. doi: 10.1513/AnnalsATS.201407-344OC.</citation>
    <PMID>25295642</PMID>
  </results_reference>
  <results_reference>
    <citation>Leary PJ, Tedford RJ, Bluemke DA, Bristow MR, Heckbert SR, Kawut SM, Krieger EV, Lima JA, Masri CS, Ralph DD, Shea S, Weiss NS, Kronmal RA. Histamine H2 Receptor Antagonists, Left Ventricular Morphology, and Heart Failure Risk: The MESA Study. J Am Coll Cardiol. 2016 Apr 5;67(13):1544-1552. doi: 10.1016/j.jacc.2016.01.045.</citation>
    <PMID>27150686</PMID>
  </results_reference>
  <results_reference>
    <citation>Leary PJ, Kronmal RA, Bluemke DA, Buttrick PM, Jones KL, Kao DP, Kawut SM, Krieger EV, Lima JA, Minobe W, Ralph DD, Tedford RJ, Weiss NS, Bristow MR. Histamine H(2) Receptor Polymorphisms, Myocardial Transcripts, and Heart Failure (from the Multi-Ethnic Study of Atherosclerosis and Beta-Blocker Effect on Remodeling and Gene Expression Trial). Am J Cardiol. 2018 Jan 15;121(2):256-261. doi: 10.1016/j.amjcard.2017.10.016. Epub 2017 Oct 20.</citation>
    <PMID>29191567</PMID>
  </results_reference>
  <results_reference>
    <citation>Leary PJ, Hess E, Barón AE, Branch KR, Choudhary G, Hough CL, Maron BA, Ralph DD, Ryan JJ, Tedford RJ, Weiss NS, Zamanian RT, Lahm T. H2 Receptor Antagonist Use and Mortality in Pulmonary Hypertension: Insight from the VA-CART Program. Am J Respir Crit Care Med. 2018 Jun 15;197(12):1638-1641. doi: 10.1164/rccm.201801-0048LE.</citation>
    <PMID>29437490</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 31, 2018</study_first_submitted>
  <study_first_submitted_qc>May 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2018</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Peter Leary</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>famotidine</keyword>
  <keyword>H2 blocker</keyword>
  <keyword>H2 antagonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Famotidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

